Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy

dc.contributor.author	Kwara, A.
dc.contributor.author	Lartey, M.
dc.contributor.author	Sagoe, K.W.
dc.contributor.author	Court, M.H.
dc.date.accessioned	2019-05-03T08:57:27Z
dc.date.available	2019-05-03T08:57:27Z
dc.date.issued	2011-01
dc.description.abstract	Some individuals have higher efavirenz plasma concentrations during rifampin-containing tuberculosis (TB) therapy, contrary to the expected induction effect of rifampin. Among HIV-infected patients without (n = 38) and with TB on rifampin-containing therapy (n = 18), we tested the hypothesis that drug-gene interaction may explain the highly variable drug interactions. Two-way analysis of variance revealed a significant interaction between CYP2B6 516G→T polymorphism and rifampin-containing therapy, suggesting that efavirenz dose adjustment may need to be individualized on the basis of the patient's genotype. © 2011 Wolters Kluwer Health \| Lippincott Williams & Wilkins.	en_US
dc.identifier.other	DOI: 10.1097/QAD.0b013e3283427e05
dc.identifier.other	Vol. 25(3): pp 388-90
dc.identifier.uri	http://ugspace.ug.edu.gh/handle/123456789/29752
dc.language.iso	en	en_US
dc.publisher	AIDS (London, England)	en_US
dc.title	Paradoxically elevated efavirenz concentrations in HIV/tuberculosis- coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy	en_US
dc.type	Article	en_US

Files

Now showing 1 - 1 of 1